Skip to content
Companies

Sensei Biotherapeutics

Targeted drug for endometrial and breast cancer

Raised to date

$348.9M

of $348.9M offered across 1 Form D filing

Investors
104
Last filed
Mar 4, 2026

About

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering next-generation cancer therapeutics. The company utilizes its proprietary biologics platform to create treatments that selectively target the tumor microenvironment. Its primary goal is to advance its pipeline candidates through clinical trials and eventually commercialize them to treat various forms of cancer.

The company's competitive advantage lies in its proprietary Tumor Microenvironment Activated Biologics (TMAB) platform. This platform is designed to generate therapeutics that can selectively disable immunosuppressive signals or activate immunostimulatory signals directly within the tumor, potentially improving efficacy and reducing side effects.

Funding

  • EquityFiled Mar 4, 2026Form D
    $348.9M/ $348.9M

Product

PIKTOR

Pathway Inhibitor

Acquired through the acquisition of Faeth Therapeutics, PIKTOR is Sensei's lead clinical program. It is an investigational multi-node inhibitor that targets the PI3K/AKT/mTOR cellular pathway, a critical pathway involved in cancer cell growth and survival. The company is developing it for the treatment of endometrial and breast cancer.

  • Inhibits the PI3K/AKT/mTOR pathway
  • Lead program in the company's pipeline
  • In development for endometrial and breast cancer

Built for

The primary audience consists of patients with advanced solid tumors, including those with endometrial and breast cancer, who are eligible for participation in clinical trials. A secondary, but critical, segment includes larger pharmaceutical companies for potential partnerships, collaborations, and future licensing agreements.

People on file